SCHEMBL7819980

SCHEMBL7819980

O=C(O)CSc1ccc(F)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
PRNP P04156 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
CYP1A2 P05177 2/20 0.42
APEX1 P27695 1/20 0.41
RIPK2 O43353 1/20 0.41
FFAR1 O14842 1/20 0.40
KEAP1 Q14145 2/20 0.40
NFE2L2 Q16236 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HK1 P19367 1/20 0.40
MCL1 Q07820 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28384726 0.83 MAPT (0.44) KDM4ECYP1A2MEN1KMT2AALDH1A1
SCHEMBL30299431 0.82 KDM4E (0.55) KDM4EPRNPRXFP1CYP1A2APEX1
SCHEMBL21450904 0.82 RIPK2 (0.52) CYP1A2APEX1RIPK2FFAR1KEAP1
SCHEMBL3071195 0.82 KDM4E (0.55) KDM4EPRNPRXFP1CYP1A2APEX1
SCHEMBL1851313 0.79 PKM (0.49) CYP1A2APEX1RIPK2FFAR1KEAP1
SCHEMBL20562926 0.79 KEAP1 (0.49) KDM4ECYP1A2APEX1RIPK2FFAR1
SCHEMBL27562903 0.78 KDM4E (0.38) KDM4ECYP1A2KMT2AMAPTHPGD
SCHEMBL21811548 0.76 CYP1A2 (0.42) KDM4EPRNPRXFP1CYP1A2APEX1
SCHEMBL5506194 0.76 LIG1 (0.47) KDM4EPRNPRXFP1CYP1A2APEX1
SCHEMBL14235422 0.74 APEX1 (0.69) CYP1A2APEX1MEN1KMT2AMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332476-B2 Fms-like tyrosine kinase inhibitors 3SM BIOTRON INC. (TW) 2022-05-17 US disclosed
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS Sagabio Co., Ltd. (TW) 2020-04-30 US disclosed
WO-2019191896-A1 FMS-LIKE TYROSINE KINASE INHIBITORS 3SM BIOTRON INC. (CN) 2019-10-10 WO disclosed
EP-1131288-A1 PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-09-12 EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
US-6166015-A Pyrrolidine derivatives-CCR-3 receptor antagonists SYNTEX (U.S.A.) INC. (US) 2000-12-26 US disclosed
WO-2000031032-A1 PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-02 WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332476-B2 Fms-like tyrosine kinase inhibitors FLT3, FLT4, FLT1 KDM4E 1341/4885PRNP 4738/4885RXFP1 2088/4885
US-20200131194-A1 FMS-LIKE TYROSINE KINASE INHIBITORS FLT3, FLT4, FLT1 KDM4E 1341/4885PRNP 4738/4885RXFP1 2088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.